Quotient Sciences, a Nottingham, England, UK-based provider of formulation development, clinical pharmacology, clinical & commercial manufacturing services to the pharmaceutical & biotech industry, received a majority stake investment from Permira.
Permira Funds will acquired the stake in Quotient from companies controlled by GHO Capital and other investors for an undisclosed sum.
The investment provides new funding to accelerate the next stage of its growth.
Led by Chief Executive Officer Mark Egerton, who will continue to lead the company Quotient along with the management team, Quotient Sciences is a global pharmaceutical development, clinical and commercial manufacturing organization, delivering customized solutions for over 150 pharmaceutical and biotech customers through both individual and integrated services.
The company, which has more than 850 employees across six operating sites in the U.K. and U.S., generates annual revenues in excess of £100m.